SYSTEMATIC REVIEW

REVISED A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa [version 2; peer review: 2 approved]

John W. Frew , Jason E. Hawkes , James G. Krueger

Laboratory for Investigative Dermatology, Rockefeller University, New York, NY, 10065, USA

V2 First published: 11 Dec 2018, 7:1923
<https://doi.org/10.12688/f1000research.17268.1>
 Latest published: 17 Jun 2019, 7:1923
<https://doi.org/10.12688/f1000research.17268.2>

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease with significant morbidity and impact on quality of life. Our understanding of the pathophysiology is incomplete, impairing efforts to develop novel therapeutic targets. Immunohistochemistry studies have produced conflicting results and no systematic evaluation of study methods and results has been undertaken to date.

Methods: This systematic review aimed to collate and describe all reports of immunohistochemical staining in HS. This systematic review was registered with PROSPERO and conducted in line with the PRISMA reporting guidelines. Potential bias was assessed using the NIH Criteria and antibodies used across various studies were tabulated and compared.

Results: A total of 22 articles were identified describing results from 494 HS patients and 168 controls. 87 unique immunohistochemical targets were identified. The overall quality of studies was sub-optimal with staining intensity confounded by active treatment. Conflicting data was identified and able to be reconciled through critical evaluation of the study methodology.

Conclusions: Keratinocyte hyperplasia with loss of cytokeratin markers co-localizes with inflammation comprising of dendritic Cells, T-lymphocytes and macrophages, which are known to play central roles in inflammation in HS. Primary follicular occlusion as a pathogenic paradigm and the principal driver of HS is unclear based upon the findings of this review. Inflammation as a primary driver of disease with secondary hyperkeratosis and follicular occlusion is more consistent with the current published data.

Keywords

Hidradenitis Suppurativa, Cytokeratin, Immunohistochemistry, Pathogenesis, Inflammation, Follicular Occlusion

Open Peer Review

Approval Status

	1	2
version 2 (revision) 17 Jun 2019		 view
	 view	 ?
version 1 11 Dec 2018		 view

1. **Gregor B. E. Jemec**, University of Copenhagen, Copenhagen, Denmark
2. **Martin M. Okun**, Fort HealthCare, Fort Atkinson, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: John W. Frew (jwfrew@gmail.com)

Author roles: **Frew JW:** Conceptualization, Data Curation, Formal Analysis, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Hawkes JE:** Data Curation, Formal Analysis, Methodology, Writing – Review & Editing; **Krueger JG:** Formal Analysis, Supervision, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: Supported in part by a grant from the National Center for Advancing Translational Sciences (NCATS) [UL1 TR001866], National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Frew JW *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Frew JW, Hawkes JE and Krueger JG. **A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa [version 2; peer review: 2 approved]** F1000Research 2019, 7:1923 <https://doi.org/10.12688/f1000research.17268.2>

First published: 11 Dec 2018, 7:1923 <https://doi.org/10.12688/f1000research.17268.1>

REVISED Amendments from Version 1

Based upon the comments of reviewers the following changes have been made:

1. The conclusions which previously read: "...primary follicular occlusion as a pathogenic paradigm and the principal driver of HS is not consistent with the findings of this review...", has been altered to now read: "...primary follicular occlusion as a pathogenic paradigm and the principal driver of HS is unclear based upon the findings of this review..."
2. Minor points raised including the sentence which read: "Increased K16 expression was increased....", has now been corrected to read: "K16 expression was increased...."

See referee reports

Introduction

Hidradenitis suppurativa (HS) is a chronic inflammatory disease, the exact pathophysiology of which remains incompletely defined¹. Numerous inflammatory mediators including TNF- α ², IL-17^{2,3}, IL-32⁴ and IL-36 subtypes^{5,6} have been implicated in the disease. However, there is an incomplete understanding of the source and triggers of these mediators and how they sustain the chronic inflammation that characterizes this disease^{1,2}. The pathogenic paradigm of HS has evolved dramatically since the first description by Velpau in 1839⁷. First thought of as an apocrinitis of infectious aetiology, it is now considered a disorder of follicular occlusion and more recently an inflammatory disease characterised by a keratinocyte mediated inflammatory response⁶. However, the variable response to topical, systemic and biologic therapies in HS⁸ indicate our understanding of disease pathophysiology is incomplete when compared to other cutaneous inflammatory diseases such as psoriasis⁹ and atopic dermatitis¹⁰. Existing studies examining the histology and immunohistochemical profiling of HS tissues represent conflicting results, for example in the degree of dermal dendritic cell infiltration^{11,12} and the production of TNF-alpha in the follicular unit^{13,14}. These results may be influenced by heterogeneous sampling methods, laboratory processing methods and data analysis¹⁵. An additional complicating factor is that clinical comorbidities which are strongly associated with disease activity in HS, such as obesity¹⁶, diabetes¹⁷, inflammatory bowel disease¹⁸, and smoking¹⁹ also impact inflammatory cell activity in the skin^{18,20–22}. Hence it remains unclear whether the presence or absence of these conditions may confound the findings of immunohistochemical studies in HS^{15,23} and whether clinical stratification of patients is required to identify distinct pathogenic pathways, which may be amenable to pharmacological intervention. This variability across studies makes comparing data problematic. To date no systematic analysis of immunohistochemical studies has been undertaken to compare results, methodology and analytical techniques.

Objectives

The objectives of this systematic review are:

- 1) To collate and describe all published reports of immunohistochemical studies in HS
- 2) To critically evaluate the sampling, laboratory and analysis techniques used in each study to determine if comparisons can be made across studies.

Methods

This systematic review was registered with PROSPERO²⁴ (Registration number CRD42018104763) and was conducted in line with the PRISMA²⁵. The STROBE statement²⁶ was used to assess the observational studies included in this study.

Data sources

Information Sources for this review encompassed Pubmed (1946-July 1 2018), Scopus (2004- July 1 2018) and Web of Science (1990-July 1 2018) as shown in Figure 1. Search strategy is presented as Table 1.

Study eligibility criteria

Eligibility criteria for this review included cohort studies, case-control studies and other observational studies with no restrictions of patient age, sex, ethnicity or language of publication. Eligible studies included those reporting the results of immunohistochemical findings in HS. Studies deemed not eligible included articles which provided no new data, only a review or summary of previously published data.

Appraisal and synthesis methods

Data collection was performed independently by 2 authors (JWF & JEH), with any disagreements regarding inclusion of citations being referred to a third author (JGK) for mediation. Information was collected using a standardized data collection form (available as Extended data²⁷) with the principal outcomes of interest being the immunohistochemical stain of interest, the site and rated intensity of staining (as described by authors), and comparison with perilesional/ unaffected/ control tissue. If data from individual patients was not available then the aggregate data was collected.

Potential sources of bias in the identified studies are acknowledged including the small size of patient cohorts, the variability in sampling and laboratory techniques, antibodies published and reactants used. Therefore these variables (where available) were collated to assess the heterogeneity of studies. Bias was also assessed using the NIH quality assessment tool for observational studies²⁸.

Results

A total of 425 non-duplicated citations were identified in the literature review (Figure 1). 398 of these articles were removed upon review of titles and abstracts against the pre-defined eligibility criteria. Full text review of the remaining 27 articles excluded 5 articles providing no new data. The remaining 22 studies^{4–6,11–14,29–43} reporting the results of 494 individual HS patients and 168 control patients were used as the basis of this systematic review.

Descriptive analysis

The demographics of the patients of the included studies are presented in Table 2. Of 494 HS patients, 180 were male (38.3%) and 290 female (61.7%) with 24 cases unreported. Ages ranged from 15–72 years. 47/50 (94%) of reported cases were smokers, 12/30 (40%) had a BMI >30, and there was no information pertaining to diabetes or family history of HS. Of the 200 documented biopsy sites 93 were axillae (46.5%), 69 were inguinal (34.5%), and 38 were genital (19%) (Table 3). 64 patients

Figure 1. PRISMA flowchart.

Table 1. Search Strategy for Systematic Review Entitled “A Systematic Review and Critical Evaluation of Immunohistochemistry Studies in Hidradenitis Suppurativa.”

Resources:	
1) Pubmed (1946-July 1 2018),	
2) Scopus (2004- July 1 2018)	
3) Web of Science (1990-July 1 2018)	
4) Published Abstracts	
5) Contact with Authors for abstracts without full text for clarification of data and methodology	
Pubmed Search Strategy:	
acne inversa OR apocrine acne OR apocrinis OR Fox-den disease OR hidradenitis axillaris OR HS OR pyoderma sinifica fistulans OR Velpeau's disease OR Verneuil's disease OR Hidradenitidis Suppurative	
AND	
IHC OR Immunohistochemistry OR Histology	

had Hurley staging with 7/64 (10.9%) Stage 1, 40/64 (62.5%) Stage 2 and 17/64 (26.6%) Stage 3. No individual Sartorius scores were reported. Where current treatment was reported, 6 patients (4.5%) were on adalimumab, 42 (31.6%) were untreated, 85 patients (63.9%) had treatment withheld prior to biopsy, and 357 cases were unreported. Lesional biopsies were taken from all studies, with 3 individual studies also taking perilesional biopsies^{6,30,41}. Age and Sex matched controls were present in 3 studies^{29,31,43} and results were stratified in a minority of studies. 2 studies stratified by disease severity^{4,12}, 7 studies stratified by lesion site^{13,33–37,39}, 5 studies stratified by treatment^{4,5,12,29,32}, and no studies stratified by comorbidities. Analysis of immunohistochemical staining methodology varied and included quantitative analysis (3 studies)^{14,30,32}, semi-quantitative analysis (14 studies)^{4,5,11–13,29,34,37–43}, and the presence or absence of staining (5 studies)^{6,31,33,35,36}. A total of 87 distinct immunohistochemical staining targets were identified (Table 4, Table 5 and Table 6).

Immunohistochemistry results

Epidermis. The epidermis of HS lesional tissue expressed the normal array of keratins (K) in the basal (K5, K14) and suprabasal (K1, K2e, K10) layers. K6, K16 and K17 staining were increased compared to healthy controls in the suprabasal epidermis in one study³⁰, however, K6 and K17 staining was not increased in the epidermis (only in non-keratinized portions of sinus tracts) in a second study³⁸. Where K6 and K17 were positive in suprabasal epidermis, K17 staining was more pronounced than K6 staining³⁰. K19 was weakly positive in acanthotic epidermis³⁷. Ki67 staining was elevated in basal and suprabasal epidermis. Normal staining patterns of desmoplakin, plakophilin and plakoglobin were seen³⁸. Cells staining positive for CD1a, CD206, CD207 and CD209 were seen throughout the epidermis⁴⁰. CD3, CD4, CD8 and to a lesser degree CD68 positive cells demonstrated epidermotropism in sites of epidermal acanthosis^{30,33}. CD29 and cholera toxin (double positive)

Table 2. Demographic data of included studies.

Number of HS Patients	Male	Female	Mean Age (Years)	Comorbidities			Biopsy Sites			Hurley Staging	mHSS Score (Mean)	Therapy	Study Reference
				Smoking	Obesity (BMI>30)	Diabetes	Family History	Axillae	Groin	Genital			
18	11	7	(Range 19–62)	NR	NR	NR	NR			NR	NR	NR	14
15	6	9	38.7	NR	NR	NR	NR	9	4	2	NR	Nil	6
24	8	16	36.5 (range 21–51)	NR	NR	NR	NR	NR	NR	NR	NR	Untreated	29
22	10	12	38.2 (Range 19–60)	NR	NR	NR	NR	NR	NR	NR	NR	NR	30
10	5	5	42 (Range 21–49)	NR	NR	NR	NR	Y	Y	N	NR	Treatment Withheld	32
20	8	12	37.5 (Range 21–51)	N=18	N=10	NR	NR	NR	NR	NR	NR	Treatment Withheld (8 weeks)	4
25	9	16	36 (Range 18–51)	NR	NR	NR	NR	NR	NR	NR	NR	Treatment Withheld (3 weeks)	5
47	19	28	42.3 (Range 22–54)	NR				NR	NR	NR	48.3 (Range 8–144)	NR	31
11	9	2	39.6 (Range 18–61)	NR	NR	NR	NR	NR	NR	NR	NR	NR	
20	6	14	40 (SD=15)	19	27.6 (4.1)	NR	NR	7	12	1	NR	Treatment withheld 3 weeks prior	12
10	1	9	38 (SD=15)	10	28.9 (SD 4.5)	NR	NR	3	7	0	NR	Treatment Withheld 3 weeks prior	
14		1	30	NR	NR	NR	NR	1		0	NR	NR	13
		1	42	NR	NR	NR	NR		1		NR	NR	
		1	25	NR	NR	NR	NR		1		NR	NR	
		1	22	NR	NR	NR	NR	1			NR	NR	
		1	45	NR	NR	NR	NR		1		NR	NR	5
		1	27	NR	NR	NR	NR	1			NR	NR	
1			38	NR	NR	NR	NR	1			NR	NR	
1			34	NR	NR	NR	NR	1			NR	NR	
		1	59	NR	NR	NR	NR		1		NR	NR	
		1	41	NR	NR	NR	NR	1			NR	NR	
		1	33	NR	NR	NR	NR	1			NR	NR	
		1	46	NR	NR	NR	NR		1		NR	NR	
		1	49	NR	NR	NR	NR		1		NR	NR	
1			31	NR	NR	NR	NR		1		NR	NR	
60	26	34	37.3 (Range 15–67)	NR	NR	NR	NR	1	6	1	NR	NR	33

Number of HS Patients	Male	Female	Mean Age (Years)	Comorbidities			Biopsy Sites			Hurley Staging	mHSS Score (Mean)	Therapy	Study Reference
				Smoking	Obesity (BMI>30)	Diabetes	Family History	Axillae	Groin	Genital			
9	1		47	NR	Y	NR	NR		1		NR	adalimumab	11
		1	31	NR	N	NR	NR		1		NR	adalimumab	
	1		24	NR	N	NR	NR	1			NR	adalimumab	
		1	32	NR	N	NR	NR			1	NR	adalimumab	
		1	58	NR	N	NR	NR			1	NR	adalimumab	
	1		58	NR	N	NR	NR			1	NR	adalimumab	
	1		36	NR	Y	NR	NR		1		NR	Nil	
	1		39	NR	N	NR	NR		1		NR	Nil	
	1		67	NR	N	NR	NR			1	NR	Nil	
16	1	15	NR	NR	N	NR	NR	3		13	NR	NR	34
5	1	4	18-36	NR	NR	NR	NR	2	3		NR	NR	35
50	18	32	11-70	NR	NR	NR	NR	39	6	5	NR	NR	36
14	11	3	16-72	NR	NR	NR	NR	2	12	0	NR	NR	37
15	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	38
22	6	16	45.6 (Range 29-69)	NR	NR	NR	NR	13	7	2	NR	NR	39
9	3	6	44 (Range 32-70)	NR	NR	NR	NR	NR	NR	NR	NR	NR	40
12	0	12	29.4 (Range 19-42)	NR	NR	NR	NR	3	0	9	NR	NR	41
36	13	23	25 (Range 20-69)	NR	NR	NR	NR	NR	NR	NR	NR	NR	42
10	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	43
494	180	290		47/50 Reported	12/30 Reported	None Reported	None Reported	93/200	69/200	38/200	Hurley 1= 7 Hurley 2= 40 Hurley 3= 17 Unknown= 430	No Individual Scores Reported adalimumab=6, untreated=42, treatment withheld=- 85, not reported= 357	

BMI= Body Mass Index mHSS= modified Hidradenitis Suppurativa Score (Sartorius Score) NR= Not Reported

Table 3. Critical Evaluation of Methodology of Studies Included in This Review.

IHC Targets	Number of HS Patients	Number of Controls	Samples Analyzed	Age/Sex Matched Controls	Stratified by severity	Stratified by lesion site	Stratified by Co-morbidities	Stratified by Treatment	Immunostaining Intensity Assessment	Study Reference
α-MSH, LL37, S100A7, MIF, TNF-α, hBD3, lysozyme	18	12	L	N	NR	N	N	N	Quantitative Immunohistomorphometry (Image J Software)	14
IL36	15	15	L, PL	NR	NR	N	N	N	Present/ Absent	6
CD3, CD56 LL37	24	9	L	Y	NR	NR	N	Y (untreated)	Semiquantitative (0-3)	29
CD1a, CD4, CD8 CD20, CD56, Factor XIIIa, IL17, NLRP3, Caspase-1	22	Yes (NR)	L, PL, U, C	NR	N	N	N	N	Cell Counting square grid x400 magnification	30
IL-23, IL-12, CD68, CD4	10	8	L, C	N	N	N	N	Y (ceased 3/52 prior)	Positive stained cells per mm ²	32
IL-32	20	10	L, C, S	N	Y	N	N	Y (ceased 8/52 prior)	Semiquantitative (+ to ++++)	4
IL-36	25	7	L, C, S	N	N	N	N	Y (ceased 3/25 prior)	Semiquantitative (+ to ++++)	5
LCN2	10	16	L	Y	N	N	N	N	Present/ Absent	31
CD11c	20	6	L	N	Y	N	N	Y	Semiquantitative (+ to ++++)	12
MMP2 hBD2 TNF-α	14	2	L, C	N	N	Y	N	N	Semiquantitative ((+ to ++++)	13
CD3, CD4, CD8, CD68 CD79 CD56	60	Yes (NR)	L, C	N	N	Y	N	N	Present or Absent	33
CD3, CD4, CD8, CD20, CD138, CD14, CD68, CD11c	9	Yes (NR)	L, C	N	N	N	N	N	Semiquantitative (+ to ++++)	11
GCDFP-15, CD15, Lysosome, S100, Ca19-9, HMB45	13	3	L, C	N	N	Y	N	N	Semiquantitative (+ to ++++)	34
CD29, CTX-FITC	5	4	L, C	N	N	Y	N	N	Present or Absent	35
AE1/AE3/PKC26/Enhanced Alkaline Phosphatase	50	Y (NR)	L, C	N	N	Y	N	N	Present or Absent	36
K1, K10, K14, K16, k17, K19, Desmoplakin 1,2, Plakoglobin, Plakophilin 1,2, Desmoglein 1,2,3, Desmocollin 1,2,3, K2e, K4, K5, K6, K7, CK8,CK9, CK10, K13, K13/15/16, K14, K17, K19, K20 Ki67	14	1	L, C	N	N	Y	N	N	Semiquantitative (+ to ++++)	37
ER, AR	15	Y (NR)	L, C	N	N	N	N	N	Semiquantitative (+ to ++++)	38
TLR2, CD3, CD19, CD56, CD68, CD11c, CD1a, CD206, CD207, CD209	22	10	L, C	N	N	Y	N	N	Semiquantitative (+ to ++++)	39
TLR 2,3,4,7,9, ICAM-1, TNF-α, IL-6, IL-10, TGF-β, α-MSH, hBD2, hBD4 IGF-1	12	Y (NR)	L, PL	N	N	N	N	N	Semiquantitative (+ to ++++)	40
hBD3, S100A7, RNase7	36	57	L, C	N	N	N	N	N	Semiquantitative (+ to ++++)	41
MMP8	10	8	L, C	Y	N	N	N	N	Semiquantitative (+ to ++++)	42
	494	168		3/22	2/22	7/22	0/22	5/22	Semiquantitative (+ to ++++)	43

Table 3: Critical Evaluation of Methodology of Studies Included in This Review Key: L= Lesional, PL= Perilesional, U= Uninvolved, C= Control S=Serum, Y= Yes, N=No, NR= Not Reported, CTx-FITC =Cholera Toxin

Table 4. Data pertaining to distribution of cells expressing Immunohistochemical markers described in this review.

Cell Type	Study	Results
Basal Keratinocytes	13	MMP2 Expressed
Suprabasal Keratinocytes	31	LCN 2 staining of suprabasal keratinocytes
Dermal Fibroblasts	13	MMP2 expressed
	7	33/51 specimens associated with ++ fibrosis
Neutrophils	13	MMP2 in keratinocytes, fibroblasts, macrophages and lymphocytes,
	30	Significant increase in number of neutrophils in dermis Dermis> Perifollicular
	31	LCN2 in neutrophils – epidermis and dermis
	7	+++ infiltrate in 29/51 specimens
Plasma Cells	7	+++ Plasma cell infiltrate in 2/51 specimens
Eosinophils	7	+++ Eosinophilic infiltrate ++ in 3/51 specimens
Histiocytes	7	+++ Infiltrate 24/51 specimens
Lymphocytes (NOS)	13	MMP2 expressed TNF alpha positivity in dermis
	44	Lymphocytes, giant cell and necrosis in established lesions
T Cells	4	CD3 + Dermis producing IL32 CD 56 + NK T cells producing IL32
	33	lymphocytic mixed infiltrate perifollicular (with unruptured terminal follicles). This consisted of CD-3 (39%), CD-4 (30%), CD-8 (14%), and positive cells (CD-4/CD-8 ratio: 2.1:1). CD-56 (0.1%) and UCHL-1 (0%) brought no conclusive results. Conspicuous was a CD-8 cell positive folliculotropism in all immuno- histologies (Figure 3). CD-8 positive lymphocytes were loosely distributed not only in the stratum basale but also in the suprabasal epithelial areas. The subepidermal inflammatory infiltrate in the area of interfollicular epidermal hyperplasia showed a comparable cellular composition: CD-3 (38%), CD-4 (26%), CD-8 (19%), CD-56 (0.2%) and UCHL-1 (0%). CD-4/CD-8 Ratio: 1.4:1. Here too, a CD-8 positive pronounced epidermotropism was impressive
	30	At perifollicular sites, quantitative analysis showed a significant increase in the mean number of CD3+, CD4+ and CD8+ T lymphocytes (CD3+ . 34 ` 20 per HPF; CD4+ , 38 ` 21; CD8+ , 12 ` 8) compared with healthy control skin (CD3+ , 9 ` 4; CD4+ , 2 ` 1; CD8+ , 1 ` 1;
	3	CD4 T cells producing IL17 in dermis
	32	CD4 T cells producing IL17 in dermis
B Cells	11,12	Pseudolymphomatous nests (see cytokine studies)
	33	Perifollicular infiltrate with unruptured terminal follicles: CD-79 (35%) Subepidermal interfollicular Infiltrate: CD-79 (33%),
Dendritic Cells	11	Successful Adalimumab treatment reduced influx of CD11c+ dendritic cells in lesional skin
	12	Number of dendritic cells stable in skin- mild elevation only
	4	Dermis producing IL32
Macrophages	13	MMP2 expressed TNF alpha positivity
	30	Significant increase in deep infiltrate
	32	Increase with co-staining of CD68/CD32 and IL12/ IL23
	33	Perifollicular infiltrate with unruptured terminal follicles: CD-68 (12%) Subepidermal interfollicular Infiltrate: CD-68 (19%),
	4	Dermis producing IL32
Mast Cells	30	Significant increase in deep infiltrate
	12	Significant increase in deep infiltrate

Table 5. Reported Immunohistochemical Staining Results Identified in this Systematic Review.

IHC Staining Target	Epidermis		Dermis	Hair Follicles		Sinus Tracts			Subcutis	Apocrine/Eccrine Glands	Study Reference
	Suprabasal Staining	Basal Staining		Infundibular Staining	ORS Staining	Type A	Type B	Type C			
CD1a			+								30
	++		+								40
			+++								12
CD3	++		++		++						30
	+	+	+								40
											32
CD4			++								12
			Interfollicular and perifollicular								33
			+		+						30
CD8											32
			+								12
	Epidermotropism		Interfollicular and perifollicular								33
CD11c		+++	+		+						30
			+++								12
											40
CD14											12
CD15										+	34
CD19	-		+								40
CD20			+++								30
			+++								12
CD29	+	+		+				+	(NOS)		35
CD32											32
CD56											30
	-		+								40
CD68	Deep> Perifollicular		++		+						30
			Interfollicular and perifollicular								33
	+		+++								40
											32
CD79			Interfollicular and perifollicular								33
CD138			Mild infiltrate								12
CD206	+		+++								40

IHC Staining Target	Epidermis		Dermis	Hair Follicles		Sinus Tracts				Subcutis	Apocrine/Eccrine Glands	Study Reference
	Suprabasal Staining	Basal Staining		Infundibular Staining	ORS Staining	Type A	Type B	Type 1	Type 2	Type 3		
CD207	+++*		+									40
CD209	++		++++									40
Cytokeratins												
AE1			Single K									36
AE3			Single K									36
PKC26			Single K									36
Factor XIIIa			DC +									12
			+		+							30
K1	Present in acanthotic epidermis			+	-	+	+	+	-	-	-	37
K2e	++					-	-	-	-	-	-	38
K4	-					-	-	-	-	-	-	38
K5	+					+	+	+	+	+	+	38
K6	-					+	+	+	+	+	+	38
K5/6\$	++++											30
K7	-					-	-	-	-	+	+	7
K8	-					-	-	-	-	-	-	38
K9	-					-	-	-	-	-	-	38
K10											-	36
	Present in acanthotic Epidermis			+	-	+	+	+	-	-	-	37
	++	+				++	++	++	-	-	-	38
K13	-						+	+	+	-	-	38
K13+15+16\$	+	+					+	+	+	+	+	38
K14	Highly positive in acanthotic epidermis			+	+	+	+	+	++	++	Sebaceous Duct and Gland +	37
K15								+	+	+	Stained apocrine glands	34
K16	Weakly positive in acanthotic epidermis			-	+	-	-	+	+	+	-	37
K17	Weakly positive in acanthotic epidermis			-	+	-	-	+	+	+	-	37
K18												38

IHC Staining Target	Epidermis		Dermis	Hair Follicles		Sinus Tracts			Subcutis	Apocrine/Eccrine Glands	Study Reference
	Suprabasal Staining	Basal Staining		Infundibular Staining	ORS Staining	Type A	Type B	Type C			
K19							+ NOS			+	36
	Weakly positive in acanthotic epidermis			-	+	-	-	-		-	37
K20						-	-	++			38
Ki67	+					-	-	-			38
ER	-					++	++	++			38
AR	-									+	39
GCDFP-15										NC	39
S100										Apocrine glands	34
Lysozyme										Eccrine glands	34
										Vulval cases only	34
HMB45	-		↓ in scarred cases							Negative all cases	14
TLR2	++		++++								40
	↓										41
TLR3	↓										41
TLR4	↓										41
TLR7	↓										41
TLR9	↓										41
ICAM-1	↓										41
TGF-β	↓										41
IGF-1	↓										41
RNase7	+++										41
MMP2	+++ / ++++	+++ / ++++	+		+++		+ NOS				42
MMP8	(Neutrophils)		+++				(Neutrophils)				13
Cholera Toxin	Slopes of papillae suprabasal epidermis,			hair follicles			+ NOS				43
Desmoplakin ₁	++					++	++	+			35
Desmoplakin ₂	++					++	++	+			38
Plakoglobin	++					++	++	+			38

IHC Staining Target	Epidermis		Dermis	Hair Follicles		Sinus Tracts			Subcutis	Apocrine/Eccrine Glands	Study Reference
	Suprabasal Staining	Basal Staining		Infundibular Staining	ORS Staining	Type A	Type B	Type C			
Plakophilin 1	++					++		++			38
Plakophilin 2						-		-			38
Desmoglein 1	++	+				++		++			38
Desmoglein 2	+					+		++			38
Desmoglein 3	++					++		++			38
Desmocollin 1	++	+				++		-			38
Desmocollin 2	++	+				++		++			38
Desmocollin 3	++					++		++			38
hBD2	↓									Negative in 12/14	1
	↓										41
hBD3	++ (suprabasal)	-			++						14
	+++	+									42
hBD4	↓										41
TNF-α	++/+++ (macrophage/lymphocytes)				++/+++					+++	13
	++	++	+	NC	↓						14
IL-6	↓										41
IL-10	↓										41
IL-12			++++								32
IL-23			++++								32
IL-17			Diffuse								30
			+++								32
IL-32		++	+++								4
IL-36	+	+++									6
	Suprabasal	+++									5
Caspase1	++										30
NLRP3	++										30
MIF	++				++						14
S100A7	++	+++			++						14
	++										42
LL-37	++				++					NC	14
		++	+++		++						29
α-MSH	++				NC						14

Key: + to ++++ = Degree of positive staining, - = reported negative staining, NC= No Change; ↓ Decreased, NOS= Not Otherwise Specified, *= Statistically significant result compared with healthy controls, §=Pan Cytokeratin Stain, DC= Dendritic Cells, Single K= Single keratinocytes,

Table 6. Immunohistochemistry stains/antibodies used in included reviews.

Target	Details	Study Reference
CD1a	CloneO10; Dako Cytomartion	30
	CloneO10; Dako Cytomartion	40
	O10 1:20 Immunotech, Prague, Czech Republic	12
CD3	clone F7.2.38; Dako)	30
	Polyclonal rabbit anti-human CD-3 dilution 1:25; Dako Cytomation Denmark A/S, Glostrup, Denmark),	33
	Polyclonal 1:150 Dako, Glostrup, Denmark	12
	Clone PC3/188A; DakoCytomation, Glostrup, Denmark	40
CD4	4B12 1:160 Monosan Uden The Netherlands	12
	monoclonal mouse anti-human CD-4 dilution 1:10; Vision Biosystems Novocastra, Newcastle, UK	33
	clone 4B12; Dako	30
	MT310 Dako	32
CD8	C9/144B 1:100 Dako	12
	monoclonal mouse anti-human CD-8 dilution 1:50; Dako Cytomation Denmark A/S	33
	clone C8/144B; Dako	30
CD11c	5D11 1:60 Novocastra Newcastle Upon Tyne, UK	12
	Clone KB90 DakoCytomation	40
CD14	MY4 1:100 Novocastra Newcastle Upon Tyne, UK	12
CD15	Not Reported	34
CD19	Clone HD37; DakoCytomation	40
CD20	clone L26 (1,4); Dako	30
	L 26 1:400 Dako	12
CD29	fluorescein-tagged B-subunit of cholera toxin (CTx-FITC) + CyChrome (Pharmingen BD Biosciences, Franklin Lakes, NJ, USA)	35
CD32	KB61 Dako	32
CD56	clone 123C3; Dako	30
	Clone MOC-1; DakoCytomation	40
	monoclonal mouse anti-human CD-56 1:50; Dako Cytomation Denmark A/S),	33
	123C3.D5 1:25 Thermo Fisher Scientific Altrincham UK	12
CD68	Clone PG- M1; Dako)	30
	monoclonal mouse anti-human CD-68 dilution 1:50; Dako Cytomation Denmark A/S)	33
	Clone EBM11; Dako Cytomation	40
	KP1 1:160 Dako	12
	EBM11 Dako	32
CD79a	monoclonal mouse anti-human CD-79 dilution 1:25; Dako Cytomation Denmark A/S)	33
	JCB117 1:100 Dako	12

Target	Details	Study Reference
CD138	B-A38 1:25 IQ Products Groningen, The Netherlands	12
CD206	Clone 19.2; BD Biosciences Pharmingen	40
CD207	Clone DCGM4; Immunotech, Marseilles, France	40
CD209	Clone DCN46; BD Biosciences Pharmingen, San Diego Ca USA	40
Cytokeratins		
Pankeratin	AE1/AE3/PKC26; Ventana Medical Systems SA, Illkirch, Cedex, France	36
Factor XIIIa	AE1/AE3 1:200 Thermo Fisher Scientific	12
	AC-1A1 1:200 Thermo Fisher Scientific	12
	clone E980.1; Leica Biosystems Newcastle, Newcastle upon Tyne, U.K.)	30
	34 Beta B4 Novo Castra Laboratories Ltd, Newcastle- upon-Tyne, UK)	37
K1	Ks2' 342' 7.1 against CK 2e (Dr L.Langbein, Heidelberg, Germany),	38
K2e		38
K4	6B10 against CK 4,	38
K5	AE 14 against CK 5,	38
K6	Ks6.KA12 against CK 6,	38
K5/6	clone M7237; Dako	30
CK7	OV-TL 12/30 and Ks7' 18 against CK 7,	38
K8	CAM 5' 2 against CK 8,	38
K9	HK9TY1 (guinea-pig polyclonal) against CK 9 (Dr L.Langbein)	38
K10	Not Reported	36
K13	LHP1 Novo Castra Laboratories Ltd, Newcastle- upon-Tyne, UK)	37
	MoAbs K8' 60 and DE-K10 against CK 10,	38
	Ks13' 1 against CK 13,	38
	Ks8' 12 against CK 13 15 16,	38
K13+15+16		38
K14	LL001 Novo Castra Laboratories Ltd, Newcastle- upon-Tyne, UK)	37
K15	LL001 against CK 14,	38
	Not Reported	34
K16	LL025 Novo Castra Laboratories Ltd, Newcastle- upon-Tyne, UK)	37
K17	E3 Novo Castra Laboratories Ltd, Newcastle- upon-Tyne, UK)	37
K19	Ks17.E3 against CK 17,	38
	Not reported	36
	B170 Novo Castra Laboratories Ltd, Newcastle- upon-Tyne, UK)	37
K20	Ks19' 1 against CK 19,	38
	IT-Ks20' 10 against CK 20	38
		38
K167	MIB 1 against Ki-67	38
	MIB1 1:100 Dako	12

Target	Details	Study Reference
ER	ER (Thermo Scientific; pretreatment EDTA, pH 9.0, dilution 1:80).	39
AR	AR (Santa Cruz; pretreatment citrate, pH 6.0, dilution 1:100)	39
GCDFP-15	Not Reported	34
S100	Not Reported	34
Lysozyme	Not Reported	34
	A0099 pAbG 1:100 rabbit antihuman Dako Corporation	14
HMB45	Not Reported	34
TLR2	Clone TL2.3; Alexis Corp. San Diego Ca USA	40
	Santa Cruz Biotechnology, Inc, Santa Cruz, California	41
TLR3	Santa Cruz Biotechnology, Inc, Santa Cruz, California	41
TLR4	Santa Cruz Biotechnology, Inc, Santa Cruz, California	41
TLR7	Santa Cruz Biotechnology, Inc, Santa Cruz, California	41
TLR9	Santa Cruz Biotechnology, Inc, Santa Cruz, California	41
ICAM-1	Beckman Coulter, Inc, Brea, California	41
TGF-β	AbD Serotec	41
IGF-1	R&D Systems, Inc, Lille, France	41
RNase7	Dako	42
MMP2	MMP-2 (cat no. AF902, LOT DUB034081, obtained from goat, 1:100 dilution, R&D Systems	13
MMP8	Dako	43
Cholera Toxin	fluorescein-tagged B-subunit of cholera toxin (CTx-FITC) + CyChrome (Pharmingen BD Biosciences, Franklin Lakes, NJ, USA)	35
Desmoplakin 1	DP 1 2±2' 15 and DP 1±2' 17 against DP I II,	38
Desmoplakin 2	DP 1 2±2' 15 and DP 1±2' 17 against DP I II,	38
Plakoglobin	PG 5' 1 and PG 11E4 (Dr M.J.Wheelock, Toledo, OH, U.S.A.) against PG,	38
Plakophilin 1	PP1-9E7 and PP1-5C2 against PP 1,	38
Plakophilin 2	PP2- 150 against PP 2,	38
Desmoglein 1	Dsg1E-P124 and Dsg1E-P23 against Dsg1,	38
Desmoglein 2	Dsg2E-G129 and Dsg2E- G96 against Dsg2,	38
Desmoglein 3	Dsg3-G194 and 5G11 against Dsg3,	38
Desmocollin 1	Dsc1-U100 against Dsc1,	38
Desmocollin 2	DC-Rab 36 (rabbit polyclonal) against Dsc2,	38
Desmocollin 3	MoAb Dsc3-U114 against Dsc3,	38

Target	Details	Study Reference
hBD2	Human beta-defensin 2 (cat no. AF 2758, LOT VJU015051, obtained from goat, 1:100 dilution, R&D Systems, Germany)	13
hBD3	Abcam, San Francisco, California	41
hBD4	1:400 rabbit antihuman Donated by Prof Schroders Labor Kiel germany	14
TNF- α	1:1000 rabbit anti-human PeproTech, Rocky Hill, N J	42
IL-6	Abcam, San Francisco, California	41
IL-10	TNF- α (code ab 6671, obtained from rabbit, 1:100 dilution, Abcam, Cambridge, UK)	13
IL-12	559071 mAbG 1:10 mouse antihuman R&D Systems	14
IL-23	AbD Serotec, Oxford, England	41
IL-17	R&D Systems, Inc, Minneapolis, Minnesota	41
IL-32	IL-12p7024945 R&D Systems	32
IL-36	IL23p19 HLT2736 Biolegend	32
Caspase1	clone AF-317-NA; R&D Systems, Wiesbaden Germany	30
NLRP3	Polyclonal R& D Systems	32
MIF	NBP-76684, Novus (Littleton, CO, U.S.A.)	4
S100A7	rabbit polyclonal anti-IL-36a (C-terminal: ab180909), rabbit polyclonal anti- IL-36b (C-terminal: ab180890) and mouse monoclonal anti-IL-36c (ab156783; all from Abcam, Cambridge, U.K.	6
LL37/ Cathelicidin	AF 1078, 1099, 2320, 1275 RnD	5
α -MSH	clone 14F468; Imgenex/Novus Biologicals, Littleton, CO, U.S.A.)	30
Tryptase	clone Ab17267; Abcam, Cambridge, U.K.	30
	MAB289 mAbG 1:100 mouse antihuman	14
	HL15-4 mAbG 1: 20,000 mouse antihuman Donated by Prof Schroders Labor Kiel germany	14
	Ab64892 pAbG 1:1000 rabbit antihuman Abcam	14
	Rabbit anti-human LL-37 [Abcam, Cambridge, UK	29
	M0939 1:500 Rabbit Anithuman Sigma	14
	PROGEN Biotechnik GmbH, Heidelberg, Germany	41
	AA1 1:800 Dako	12
	clone AA1; Dako	30

staining cells were seen on the slopes of papillae of the epidermis³⁵. hBD2 (human beta defensin) staining was decreased throughout the epidermis in two studies^{13,41} whilst hBD3 staining was increased throughout the suprabasal epidermis^{14,42}, however only significantly in Hurley Stage 1 and 2 patients ($p=0.045$)⁴². hBD4 was decreased in suprabasal epidermis compared to healthy controls ($p=0.001$)⁴¹. Contradictory findings were seen in toll like receptor (TLR) 2 staining with an increase in the epidermis co-localizing with dendritic cells and macrophages in one study⁴⁰ but suppressed in a second study⁴¹. Levels of TLR3, TLR4, TLR7, TLR9, ICAM-1, TGF-Beta and IGF-1 were only assessed by one study and all were suppressed throughout the epidermis compared with controls⁴¹. RNAase7 was increased in expression compared to healthy controls ($p<0.05$)⁴². MMP2 was positively expressed in keratinocytes throughout the epidermis¹³ and MMP8 in neutrophils within the epidermis⁴³. TNF- α was highly expressed in macrophages and lymphocytes present in the epidermis, particular in the basal layers^{13,14} and NLRP3, MIF, S100A7, LL37/Cathelicidin and α -MSH all positive in suprabasal keratinocytes^{30,41}. IL-6 and IL-10 were reported as suppressed compared to healthy control skin⁴¹, however, IL-36 subtypes were highly expressed in epidermal keratinocytes (more suprabasal than basal)^{5,6} with IL-32 also positive in the stratum granulosum⁴.

Dermis. CD1a, CD11c, CD206, CD207, CD209 and Factor XIIIa positive cells were identified in the dermis in three separate studies^{12,30,40}, however the degree of infiltration varied. Dermal infiltrates of CD3, CD4, and CD8 positive cells, continuous with the epidermal infiltrates were a consistent feature of lesional HS dermis and were increased over controls^{30,33}. The distribution of these cells was most pronounced in the interfollicular dermis (ie. towards the papillary slopes) and perifollicularly (ie. peri-infundibularly)^{30,33}. CD56, CD68 and CD138 positive cells were diffusely seen throughout the dermis⁴⁰. CD19 and CD20 positive pseudolymphoid follicles have been noted in other studies^{30,40}. Single keratinocytes have also been identified in the dermis which stain with pancytokeratin markers (AE1/AE3/PKC26)³⁶. Inflammatory cells in the dermis co-localized with TNF- α ^{13,14}, LL-37/cathelicidin²⁹, IL-12³², IL-23³², IL-17^{30,32}, IL-32⁴, TLR2⁴⁰ and MMP8⁴³. MMP2 co-localized with macrophages and fibroblasts¹³. IL-36 was not identified in the dermis^{5,6}.

Hair follicle. Cytokeratin staining of the follicular apparatus is consistent with normal K14, K16 and K17 staining. CD29 positive cells were identified in the infundibulum³⁵. CD3, CD4, CD8, CD68, Factor XIIIa positive cells were seen within the outer root sheath (ORS) contiguous with dense peri-follicular inflammation in the adjacent dermis^{30,33}. The presence of inflammatory cells co-localized with MMP2¹³, TNF- α ^{13,14}, and LL37/cathelicidin^{13,29}. hBD3^{13,42} and MIF¹³ also stained positive in the ORS. One conflicting study reported no change in TNF- α staining of the follicular unit¹³.

Sinus tracts. Staining patterns differed between superficial keratinized sinus tracts and deeper, inflamed non-keratinized sinus tracts. Normal epidermal cytokeratin staining was seen in the

keratinized superficial portion of sinus tracts including K1, K10, K14^{36–38}. Ki67 was elevated and CD29 positive cells were also identified in sinus tracts³⁵. Ki67 stained in both keratinized and non-keratinised portions of the sinus tract³⁸. K19 staining was absent in keratinized portions of sinus tracts³⁷. In deeper, inflamed, non-keratinized portions of the sinus tracts, K16, K17 and K19 were positive, with loss of K1, K10 and adhesions molecules including DG1 (desmoglein 1) and DSC1 (desmocollin 1)^{37,38}. Apocrine gland nuclei stained weakly positive for estrogen receptor³⁹ and androgen receptor³⁹, and these results were reported as no different from control specimens³⁹. Lysozyme staining of apocrine glands was seen in cases of vulval HS only³⁴.

Immunohistochemistry methods. The list of antibodies used for IHC staining is presented in [Table 6](#). Consistent antibodies were used for CD1a; CD20 and tryptase staining, whilst different antibodies were used for other staining targets. Antibodies used were not described in two studies^{34,36}.

Assessment of Bias. The result of bias assessment using NIH criteria is presented in [Table 7](#). All 22 articles clearly stated the research question of interest with well-defined study populations. The application of inclusion and exclusion criteria, or the calculation of sample size, or effect estimates were not described in any study. Exposures (ie. the presence of disease) were established and measured in all studies prior to the outcome measures (IHC staining) being assessed and the disease was established for such a time that a relationship between exposure and outcome would be identified if one existed. Different levels of exposure (severity of disease) was taken into account in only two studies^{4,12} and was consistently measured using Hurley staging across all studies. No articles accounted for all possible confounding variables such as obesity, diabetes, family history or smoking status ([Table 3](#)).

Discussion

Quality of data and risk of bias

The overall quality of data in this systematic review was sub-optimal with poor correction for potential confounding factors with only two of the 22 studies using objective measurement systems for IHC staining intensity^{4,12}. The proportion of smokers was elevated (94%) compared to the rates of smoking in the HS population at large (70–89%)⁴⁵. A number of studies (17/22) did not stratify results by treatment therefore there is a risk that staining intensity of pro-inflammatory mediators may be reduced due to concomitant treatment at the time of biopsy. The use of de-paraffinized tissue in retrospective studies^{30,33,34} can lead to false negatives in IHC dependent upon the preparation method of the original sample and the de-paraffinization process¹⁵. Hence there are factors in the population studied in this review which may bring into question the reliability of staining quantification. However, the presence or absence of IHC staining, particularly when confirmed in multiple studies is still considered reliable despite the risks of bias.

Conflicting results

Conflicting results were identified in dermal CD1a staining^{12,30,40}, dermal CK19 staining^{36–38}, Epidermal TLR2 staining^{40,41} and TNF alpha staining in the follicular infundibulum^{13,14}. Regarding

Table 7. NIH Risk of Bias.

Study Reference	1. Was the research question or objective in this paper clearly stated?	2. Was the study population clearly specified and defined?	3. Was the participation rate of eligible persons at least 50%?	4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	5. Was a sample size justification, power description, or variance and effect estimates provided?	6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	10. Was the exposure assessed more than once over time?	11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	12. Were the outcome assessors blinded to the exposure status of participants?	13. Was loss to follow-up after baseline 20% or less?	14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?
Emelianov <i>et al.</i> ¹⁴	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Hessam <i>et al.</i> ⁹	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Thomi <i>et al.</i> ²⁹	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Lima <i>et al.</i> ³⁰	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Schlapbach <i>et al.</i> ³²	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Thomi <i>et al.</i> ⁴	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Thomi <i>et al.</i> ⁵	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Wolk <i>et al.</i> ³¹	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Van der Zee <i>et al.</i> ¹²	Y	Y	N/A	N	N	Y	Y	Y	Y	Y	Y	NR	N/A	N
Mozeika <i>et al.</i> ¹³	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Jon Laffert <i>et al.</i> ³³	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N

Study Reference	1. Was the research question or objective in this paper clearly stated?	2. Was the population clearly specified and defined?	3. Was the participation rate of eligible persons at least 50%?	4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	5. Was a sample size justification, power description, or variance or effect estimates provided?	6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	10. Was the exposure(s) assessed more than once over time?	11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	12. Were the outcome assessors blinded to the exposure status of participants?	13. Was loss to follow-up after baseline 20% or less?	14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?
Van der Zee <i>et al.</i> ¹¹	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Heller <i>et al.</i> ³⁴	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Griadecki <i>et al.</i> ³⁵	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Fisken <i>et al.</i> ³⁶	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Kurokawa <i>et al.</i> ³⁷	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Kurzen <i>et al.</i> ³⁸	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Buier <i>et al.</i> ³⁹	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Hunger <i>et al.</i> ⁴⁰	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Derno <i>et al.</i> ⁴¹	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Hofmann <i>et al.</i> ⁴²	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Tsaousi <i>et al.</i> ⁴³	Y	Y	N/A	N	N	Y	Y	N	Y	N	Y	NR	N/A	N
Total	22/22	22/22	N/A	0/22	0/22	22/22	22/22	2/22	22/22	1/22	22/22	NR	N/A	0/22

Y: Yes; N= No, NR= Not Reported N/A = Not Applicable

CD1a staining, two of the studies reported only a mild dermal infiltrate of CD1a positive cells^{30,40}, with a third study demonstrating a significant infiltration of these cells¹². This third study clearly documented all treatment was withheld 3 weeks prior to the biopsies being taken¹², whereas there is no description in the other two articles regarding the discontinuation or ongoing use of treatments^{30,40}. Therefore, with the possibility of partially treated disease, an artificial reduction in the number of dermal dendritic cells is a possibility as treatment for HS (such as adalimumab) has been demonstrated to effectively reduce the infiltration of dendritic cells *in vivo*¹². Similarly, studies examining TNF- α staining also differed in their stratification of patient based upon active treatment^{13,14}. Significant reductions in TNF α staining were seen in the study with no documentation of treatment cessation¹⁴ when compared to the one study with clear documentation that all patients had treatment ceased prior to biopsy¹³. K19 staining was reported negative in all areas of the sinus tracts in one study³⁷, whereas two additional studies^{36,38} described positive K19 staining in sinus tracts (one study non-specifically³⁶ and the second in the deep inflamed, non-keratinized epithelium of the tract³⁸). The difference between these staining patterns may be explained by the presence of inflammation. Kurzen *et al.*³⁸ described the presence of K19 staining in non-keratinized epithelium of the deep sinus tracts only when associated with inflammation (Type 3 epithelia), staining was negative when no inflammation was present (Type 2 epithelia)³⁸. Kurokawa *et al.* did not differentiate between inflamed and non-inflamed non-keratinized epithelium in their study³⁷, and noted that the lesser degree of inflammation seen histologically may explain their differing results in comparison to Kurzen's study³⁷.

Localization of production of inflammatory mediators

IHC staining, in particular co-staining with cellular markers and cytokines has enabled the localization of inflammatory mediators in order to ascertain the functional aspects of infiltrating inflammatory cells in HS, particularly highlighting the strong T_H17 polarity of inflammation in HS³. A schematic representation of the pathogenesis of HS based upon the findings of this review is presented in Figure 2. This highlights the inter-relationship between inflammation and hyperkeratinization. Localization of TNF- α ¹³, IL-12³², IL-23³² and IL-32⁴, TLR2⁴⁰, MMP2¹³, MMP8⁴³ and LL-37/cathelicidin^{14,29} production to infiltrating dermal macrophages and lymphocytes as well as localization of IL-36 subtypes⁵, LL-37/cathelicidin^{14,29}, IL-1 β ³² and IL-22³² to keratinocytes illustrate the feed forward mechanisms similar to those seen in psoriasis⁹ and atopic dermatitis¹⁰ which likely contribute to persistent inflammation in HS. Rather than keratinocytes being innocent bystanders, these IHC findings demonstrate the central role keratinocytes play as producers of key inflammatory mediators as well as mediators of products (such as TGF- β and ICAM)⁴¹ that may contribute to fibroblast dysregulation and hypertrophic scarring⁴⁶. A remaining unanswered question includes the temporal relationship between keratinocyte hyperproliferation and the activation of inflammatory cells infiltrating the dermis and epidermis in HS.

Insights into pathophysiology of HS

The current pathophysiological paradigm of HS is one of follicular infundibular occlusion leading to follicle rupture and

a resultant inflammatory cascade¹. This paradigm was based on the pivotal work of Shelley and Cahn in 1955⁴⁷, whom demonstrated the induction of HS after application of belladonna impregnated tape to manually epilated axillae of 12 men. Only 3 of the 12 men developed the lesions described, and infection from the manual epilation procedure could not be excluded as a cause of the lesions, but this study enabled the paradigm to slowly shift away from one of apocrinitis, which had been in place since the original descriptions of the disease⁷. Detailed descriptions of infundibular hyperkeratosis (also termed poral occlusion) were made by Jemec *et al.*⁷ and demonstrated the secondary involvement of apocrinitis in HS lesions. Jemec noted that poral occlusion was seen to occur alongside inflammation, but there was no suggestion of causation in one direction or another⁷.

Although individual cases of epidermal hyperkeratosis in the absence of inflammation are noted^{7,33}, these cases are established or chronic lesions associated with significant fibrosis which is documented to be associated with reduce inflammatory infiltrate^{7,33}. A consistent finding in all studies of this review is the co-localization of infundibular ORS keratinocyte hyperplasia with CD3, CD4, CD8 and CD68 positive inflammatory cells expressing TNF- α , IL-12, IL-23 and IL-32^{4,13,32,40,43}. K19 is also documented as positive in the infundibulum suggesting keratinocyte hyperplasia^{36–38}. However, it remains unclear whether keratinocyte hyperplasia induces the inflammatory cascade or if the inflammatory cascade induces the keratinocyte hyperplasia. The presence of inflammation in clinically normal, peri-lesional HS skin is well documented^{4,30,33} implying the existence of a pre-clinical inflammation preceding symptoms of follicular occlusion. This is consistent with recent findings in acne pathogenesis that suggest that inflammation precede follicular hyperkeratosis and development of microcomedones⁴⁸ and is also pivotal in the ongoing development of nodulocystic acne and acne scars⁴⁹. This pre-clinical inflammation is also consistent with the pathogenic paradigm in psoriasis and atopic dermatitis^{9,10} with inflammation driving epidermal hyperkeratosis and alterations in keratinocyte maturation, consistent with the spongiform infundibulofolliculitis seen in established lesions of HS⁵⁰. Our disparate findings in K19 staining in deep non-keratinized sinus tract epithelia with and without inflammation^{37,38} also fit with this paradigm. In contrast, findings which would hold consistency with the current follicular occlusion paradigm would include infundibular occlusion preceding the development of inflammation, as well as alterations to desmosomal and hemidesmosomal proteins which would allow for rupture of the occluded follicles in order to drive the development of dermal inflammation and sinus tract formation. Although Danby *et al.*⁵¹ reports reduced PAS positivity in the basement membrane zone at the sebo-follicular junction associated with inflammation in HS, it is likely that the reduced basement membrane integrity is secondary to inflammation and release of TGF- β and MMP2⁵² (cytokines known to be altered in HS lesional skin and consistent with an abnormal wound healing response) rather than the follicular rupture being the primary driver of inflammation.

A more consistent hypothesis which accounts for the observed results of this review would be that of subclinical inflammation

Figure 2. Schematic Representation of Immunohistochemical findings in hidradenitis suppurativa. Immunological 'priming' occurs due to the contribution of adipose tissue, genetic susceptibility, smoking-related inflammatory mediators and obesity related pro-inflammatory signals and the composition of the microbiome. Increased activity of cDC1, cDC2 and T cells lead to both keratinocyte hyperplasia via the actions of IL-12 and IL-23, as well as a T_H17 predominant immune response. Alterations of antimicrobial peptides (AMPs) also occur throughout the epidermis. IHC staining localizes Langerhan cells and activated dendritic cells to the epidermis and the dermo-epidermal junction. A population of epidermotropic CD8 T cells are also present. IHC staining indicates a mixed inflammatory infiltrate in the dermis, with contributions from Dendritic cells, B cells, T cells and plasma cells. Within sinus tracts, adhesion molecules are preserved, but inflammation associated with non-keratinized sinus tracts leads to a loss of K19. The development of scarring and sinus tracts is associated with MMP2, ICAM-1 and TGF-Beta, with possible augmentation of ICAM-1 and TGF-B signaling via specific components of the microbiome. TNF- α , PGE2 and CXCL2 then lead to additional feed forward mechanisms perpetuating the inflammatory cycle.

(due to a variety of triggers and immunological primers as illustrated in Figure 2) driving keratinocyte proliferation in the interfollicular epidermis and the follicular ORS, with follicular occlusion being a secondary phenomenon (mediated by TLR2 and IL-1 α as documented in the development of comedones)⁵³. The development of sinus tracts and hypertrophic scarring may also be mediated by the keratinocyte inflammatory response given the alterations in important wound healing mediators including TGF- β , ICAM-1 and comparisons by other authors of an altered wound healing response⁸ in HS. This comparison would be appropriate given the high levels

of dermal MMP2¹³ and MMP8⁴³; the loss of keratinocyte maturation markers (K2e, K10, K19)^{36–38} adhesion molecules (DG1 and DCN2)³⁸ in the non keratinized inflamed epithelium of the deep dermis; suppressed levels of ICAM-1⁴¹ (seen impaired wound healing⁵⁴) and TGF- β ⁴¹ which leads to the dysregulation of TGF- β receptor ratio on fibroblasts which is linked with the development of hypertrophic scarring^{46,54} seen in HS. These alterations to keratinocyte maturation are reminiscent of epithelial mesenchymal transition (EMT)⁵² which may also explain the presence of free keratinocytes in the dermis in established lesions of HS^{7,36}. Indeed, as ICAM-1 is up-regulated

by pro-inflammatory mediators⁵⁴, the low level of ICAM-1 noted appears paradoxical, however specific bacteria (including *Porphyromonas* species) which have been associated with HS^{44,55} can suppress ICAM-1 production as an immune evasion strategy⁵⁶. This implies that exogenous triggers (possibly including bacterial stimuli) can be a common cause for the initial inflammatory cascade as well as the development of tunneling and hypertrophic scarring in HS.

Conclusions

This systematic review of immunohistochemical staining of lesions in HS has highlighted the heterogeneity of studies and the methodological issues, which bring into question some of the results of IHC staining in HS lesions. The design of studies and variable reporting of potential confounding factors (such as ongoing or previous treatments) makes it impossible to compare staining intensity across studies. The results of existing studies suggest a florid inflammatory reaction comprising of T-lymphocytes, macrophages and dendritic cells with a strong Th-17 signature along with a keratinocyte mediated IL-36 inflammatory loop associated with keratinocyte hyperproliferation. The follicular occlusion paradigm as a primary driver of HS is unclear given the findings of this review and other histological and cytokine studies and inflammation as a primary driver of disease with secondary hyperkeratosis and occlusion is a plausible hypothesis.

Data availability

All data underlying the results are available as part of the article and no additional source data are required

Extended data

OSF: Extended data. Data collection sheet. <https://doi.org/10.17605/OSF.IO/2JKPW>²⁷

Licence: CC0 1.0 Universal

Reporting guidelines

OSF: PRISMA Checklist for 'A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa'. <https://doi.org/10.17605/OSF.IO/2JKPW>²⁷

Licence: CC0 1.0 Universal

Grant information

Supported in part by a grant from the National Center for Advancing Translational Sciences (NCATS) [UL1 TR001866], National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Hoffman LK, Ghias MH, Lowes MA: **Pathophysiology of hidradenitis suppurativa.** *Semin Cutan Med Surg.* 2017; **36**(2): 47–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Melnik BC, John SM, Chen W, *et al.*: **T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities.** *Br J Dermatol.* 2018; **179**(2): 260–272.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Moran B, Sweeney CM, Hughes R, *et al.*: **Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which is Corrected by Anti-TNF Therapy.** *J Invest Dermatol.* 2017; **137**(11): 2389–2395.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Thomi R, Yerly D, Yawalkar N, *et al.*: **Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.** *Br J Dermatol.* 2017; **177**(5): 1358–1366.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Thomi R, Kakeda M, Yawalkar N, *et al.*: **Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa.** *J Eur Acad Dermatol Venereol.* 2017; **31**(12): 2091–2096.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hessam S, Sand M, Gambichler T, *et al.*: **Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop.** *Br J Dermatol.* 2018; **178**(3): 761–767.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jemec GB, Hansen U: **Histology of hidradenitis suppurativa.** *J AM Acad Dermatol.* 1996; **34**(6): 994–999.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Negus D, Ahn C, Huang W: **An update on the pathogenesis of hidradenitis suppurativa: implications for therapy.** *Expert Rev Clin Immunol.* 2018; **14**(4): 275–283.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hawkes JE, Chan TC, Krueger JG: **Psoriasis pathogenesis and the development of novel targeted immune therapies.** *J Allergy Clin Immunol.* 2017; **140**(3): 645–653.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Brunner PM, Guttman-Yassky E, Leung DY: **The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.** *J Allergy Clin Immunol.* 2017; **139**(4S): S65–S76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- van der Zee HH, de Ruiter L, van den Broecke DG, *et al.*: **Elevated levels of tumour necrosis factor (TNF)- α , interleukin (IL)-1 β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF- α and IL-1 β .** *Br J Dermatol.* 2011; **164**(6): 1292–1298.
[PubMed Abstract](#) | [Publisher Full Text](#)
- van der Zee HH, Laman JD, de Ruiter L, *et al.*: **Adalimumab (antitumour necrosis factor- α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an *in situ* and *ex vivo* study.** *Br J Dermatol.* 2012; **166**(2): 298–305.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mozeika E, Pilmane M, Nürnberg BM, *et al.*: **Tumour necrosis factor- α and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa.** *Acta Derm Venereol.* 2013; **93**(3): 301–304.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Emelianov VU, Bechara FG, Glasera R, *et al.*: **Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa.** *Br J Dermatol.* 2012; **166**(5): 1023–1034.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Wester K, Wahlund E, Sundström C, *et al.*: **Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen.** *Appl Immunohistochem Mol Morphol.* 2000; **8**(1): 61–70.
[PubMed Abstract](#)
- Ergun T: **Hidradenitis suppurativa and the metabolic syndrome.** *Clin Dermatol.* 2018; **36**(1): 41–47.
[PubMed Abstract](#) | [Publisher Full Text](#)

17. Garg A, Birabakaran M, Strunk A: **Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States.** *J Am Acad Dermatol.* 2018; **79**(1): 71–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Lukach AJ, Saul MI, Ferris LK, *et al.*: **Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease.** *Dig Dis Sci.* 2018; **63**(3): 755–760.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Garg A, Papagermanos V, Mldura M, *et al.*: **Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A.** *Br J Dermatol.* 2018; **178**(3): 709–714.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Scgambato JA, Jones BA, Caraway JW, *et al.*: **Inflammatory profile analysis reveals differences in cytokine expression between smokers, moist snuff users, and dual users compared to non-tobacco consumers.** *Cytoine.* 2018; **107**: 43–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Spoto B, Di Betta E, Mattace-Raso F, *et al.*: **Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesity.** *Nutr Metab Cardiovasc Dis.* 2014; **24**(10): 1137–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Rehman K, Akash MS: **Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked?** *J Biomed Sci.* 2016; **23**(1): 87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Zhou X, Fragala MS, McElhaney JE, *et al.*: **Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research.** *Curr Opin Clin Nutr Metab Care.* 2010; **13**(5): 541–547.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Frew J, Hawkes J, Krueger J: **A Systematic Review of Immunohistochemical studies in Hidradenitis Suppurativa.** *PROSPERO.* 2018; CRD42018104763. Accessed 27 August 2018.
[Reference Source](#)
25. Moher D, Liberati A, Tetzlaff J, *et al.*: **Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.** *PLoS Med.* 2009; **6**(7): e1000097.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. von Elm E, Altman DG, Egger M, *et al.*: **The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.** *J Clin Epidemiol.* 2008; **61**(4): 344–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Frew J: **A Systematic Review and Critical Evaluation of Immunohistochemical Associations in Hidradenitis Suppurativa.** 2018.
<http://www.doi.org/10.17605/OSF.IO/2JKPW>
28. NIH NIOH: **Quality Assessment Tool for Observational Cohort and Cross Sectional Studies.** 2018. Accessed 30 July 2018.
[Reference Source](#)
29. Thoni R, Schlapbach C, Yawalkar N, *et al.*: **Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response.** *Exp Dermatol.* 2018; **27**(2): 172–177.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Lima AL, Karl I, Giner T, *et al.*: **Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa.** *Br J Dermatol.* 2016; **174**(3): 514–521.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Wolk K, Wenzel J, Tsaousi A, *et al.*: **Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa.** *British J Dermatol.* 2017; **177**(5): 1385–1393.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Schlapbach C, Hanni T, Yawalkar N, *et al.*: **Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa.** *J Am Acad Dermatol.* 2011; **65**(4): 790–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. von Laffert M, Stadie V, Wohlrab J, *et al.*: **Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae.** *Br J Dermatol.* 2011; **164**(2): 367–371.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Heller DS, Haefner HK, Hameed M, *et al.*: **Vulvar hidradenitis Suppurativa. Immunohistochemical evaluation of apocrine and eccrine involvement.** *J Reprod Med.* 2002; **47**(9): 695–700.
[PubMed Abstract](#)
35. Gniatecki R, Jemec GB: **Lipid raft-enriched stem cell-like keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa.** *Exp Dermatol.* 2004; **13**(6): 361–363.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Fismen S, Ingvarsson G, Moseng D, *et al.*: **A clinical-pathological review of hidradenitis suppurativa: using immunohistochemistry one disease becomes two.** *APMIS.* 2012; **120**(6): 433–440.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Kurokawa I, Nishijima S, Kusomoto K, *et al.*: **Immunohistochemical study of cytokeratins in hidradenitis suppurativa (acne inversa).** *J Int Med Res.* 2002; **30**(2): 131–136.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Kurzen H, Jung EG, Hartschuh W, *et al.*: **Forms of epithelial differentiation of draining sinus in acne inversa (hidradenitis suppurativa).** *Br J Dermatol.* 1999; **141**(2): 231–239.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Buiner MG, Wobbes T, Klinkenbilij JH, *et al.*: **Immunohistochemical analysis of steroid hormone receptors in hidradenitis suppurativa.** *Am J Dermatopathol.* 2015; **37**(2): 129–132.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Hunger RE, Surovy AM, Hassan AS, *et al.*: **Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor.** *Br J Dermatol.* 2008; **158**(4): 691–697.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Dreno B, Khammari A, Brocard A, *et al.*: **Hidradenitis suppurativa: the role of deficient cutaneous innate immunity.** *Arch Dermatol.* 2012; **148**(2): 182–186.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Hofmann SC, Saborowski V, Lange S, *et al.*: **Expression of innate defense antimicrobial peptides in hidradenitis suppurativa.** *J Am Acad Dermatol.* 2012; **66**(6): 966–974.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Tsaousi A, Witte E, Witte K, *et al.*: **MMP8 Is Increased in Lesions and Blood of Acne Inversa Patients: A Potential Link to Skin Destruction and Metabolic Alterations.** *Mediators Inflamm.* 2016; **2016**: 4097574.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Ring HC, Thorsen J, SAunte DM, *et al.*: **The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls.** *JAMA Dermatol.* 2017; **153**(9): 897–905.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Micheletti RG: **Hidradenitis suppurativa: current views on epidemiology, pathogenesis, and pathophysiology.** *Semin Cutan Med Surg.* 2014; **33**(3 Suppl): S48–S50.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Zhu Z, Ding J, Tredget EE: **The molecular basis of hypertrophic scars.** *Burns Trauma.* 2016; **4**: 2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Shelley WB, Cahn MM: **The pathogenesis of hidradenitis suppurativa in man; experimental and histologic observations.** *AMA Arch Derm.* 1955; **72**(6): 562–565.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Del Rosso JQ, Kircik LH: **The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician?** *J Drugs Dermatol.* 2013; **12**(8 Suppl): s109–115.
[PubMed Abstract](#)
49. Holland DB, Jeremy AH: **The role of inflammation in the pathogenesis of acne and acne scarring.** *Semin Cutan Med Surg.* 2005; **24**(2): 79–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Boer J, Weltvreden EF: **Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions.** *Br J Dermatol.* 1996; **135**(5): 721–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Danby FW, Jemec GB, Marsch WCh, *et al.*: **Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support.** *Br J Dermatol.* 2013; **168**(5): 1034–1039.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Kalluri R, Weinberg RA: **The basics of epithelial-mesenchymal transition.** *J Clin Invest.* 2009; **119**(6): 1420–1428.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Selway JL, Kurczab T, Kealey T, *et al.*: **Toll-like receptor 2 activation and comedogenesis: implications for the pathogenesis of acne.** *BMC Dermatol.* 2013; **13**: 10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Koivisto L, Heino J, Hakkinen L, *et al.*: **Integrins in Wound Healing.** *Adv Wounds Care (New Rochelle).* 2014; **3**(12): 762–783.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Guen-Reville H, Jais JP, Ungeheuer MN, *et al.*: **The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study.** *Clin Infect Dis.* 2017; **65**(2): 282–291.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Huang GT, Kim D, Lee JK, *et al.*: **Interleukin-8 and intercellular adhesion molecule 1 regulation in oral epithelial cells by selected periodontal bacteria: multiple effects of Porphyromonas gingivalis via antagonistic mechanisms.** *Infect Immun.* 2001; **69**(3): 1364–1372.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 25 June 2019

<https://doi.org/10.5256/f1000research.21501.r49996>

© 2019 Okun M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Martin M. Okun

Fort HealthCare, Fort Atkinson, WI, USA

My concerns have been satisfactorily addressed with these changes. I support indexing.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 19 March 2019

<https://doi.org/10.5256/f1000research.18880.r45666>

© 2019 Okun M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Martin M. Okun

Fort HealthCare, Fort Atkinson, WI, USA

This is a thorough, thoughtful, and valuable contribution to the scientific literature on pathogenesis of hidradenitis suppurativa.

The principal advances of the systematic review are:

- cogently advances a reasonable hypothesis to explain decreased levels of inflammatory marker density in some studies as due to the lack of treatment interruption;
- links the presence of certain hyperproliferative keratin markers (K19) to the presence of

concomitant inflammation

- collates evidence from multiple studies demonstrating the presence of keratinocyte-derived pro-inflammatory biomarkers, reinforcing the concept that keratinocytes are actively contributing to the inflammatory milieu

The authors advance the hypothesis that follicular occlusion is secondary to inflammation, based on:

- absence of evidence of follicular occlusion without inflammation (though absence of evidence is not equivalent to the evidence of absence)
- presence of inflammation in clinically normal perilesional skin (though inflammation could be spill-over from adjacent inflamed skin)
- analogies with other inflammatory skin diseases
- presence of K19 staining only in inflamed sinus tracts (though the relevance of this observation for the pathogenesis of HS is uncertain)

In short, this hypothesis is plausible but the conclusion that "primary follicular occlusion as a pathogenic paradigm and the principal driver of HS is not consistent with the findings of this review" seems too sweeping a statement based on the information provided. The authors should consider altering this conclusion in line with the limitations of available data.

As a minor issue, there is an unnecessary repetition in the second sentence of the Immunohistochemistry results, epidermis section: "Increased K6, K16 and K17 staining were increased..."

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Not applicable

Are the conclusions drawn adequately supported by the results presented in the review?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 25 February 2019

<https://doi.org/10.5256/f1000research.18880.r42315>

© 2019 Jemec G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gregor B. E. Jemec

University of Copenhagen, Copenhagen, Denmark

The authors provide a systematic review of immunohistochemical studies of hidradenitis suppurativa (HS).

The clearly stated objectives are:

1. To collate and describe all published reports of immunohistochemical studies in HS.
2. To critically evaluate the sampling, laboratory and analysis techniques used in each study to determine if comparisons can be made across studies.

The review was registered with PROSPERO and conducted in line with the PRISMA. The STROBE statement was used to assess the observational studies included in the study. A PRISMA flow chart and a search strategy are provided accordingly.

The authors adequately discuss the confounding factors and risk of bias, which both are significant weaknesses identified in the literature by this manuscript based on limited studies.

Only 22 articles were identified describing results from 494 HS patients (average 22 pts/study) and only 168 controls. Furthermore, 87 unique immunohistochemical targets were identified adding to the scarcity of hard data. It is therefore less surprising that conflicting data were found. The authors are however able to provide a realistic analysis of the data taking these limitations into account, and, in addition, provide coherent analyses and a testable paradigm for the pathomechanisms of HS.

The paper provides an excellent overview of the limited number of explorative immunohistochemical studies of HS, and thus provides an important stepping-stone to further studies.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Not applicable

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research